Photographer: Andrey Rudakov/Bloomberg

Brexit Shock Dodged by U.K. Pharma as Innovation Spurs Deals

  • Companies such as Martindale, Morningside said to explore sale
  • Pharma companies seek to cash out despite market volatility

As the U.K.’s vote to leave the European Union wreaks havoc on the economy, dealmaking momentum in the country’s pharmaceutical industry is showing no signs of letting up.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.